Navigation Links
Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimer's Disease Compound
Date:10/1/2008

nition (ADAS-cog), which measures cognitive function with an emphasis on memory, and the Alzheimer's Disease Cooperative Study - Activities of Daily Living scale (ADCS-ADL), which measures the ability to independently perform daily activities such as eating, bathing, and using the telephone. A number of optional biomarker substudies will be available to patients that will utilize brain-scanning and biochemical techniques to detect markers of Alzheimer's disease.

Alzheimer's disease is a progressive neurodegenerative condition that is the most common cause of dementia, accounting for 60 to 80 percent of cases(1). Estimates show that 6-8 percent of people over age 65 are affected by Alzheimer's disease(2), totaling approximately 5.5 million people in the United States alone(3). Every 72 seconds, an American is developing Alzheimer's disease(4), and it is the seventh-leading cause of death in the United States(5). The direct and indirect health care costs associated with Alzheimer's disease and other dementias in the U.S. are estimated to be about $150 billion(6). In 2005, the total cost worldwide of dementia, of which Alzheimer's disease is the most common cause, was estimated at $315.4 billion(7). The burden to caregivers and health care costs can increase dramatically in the late stages of Alzheimer's disease, when patients cannot maintain independent function and are frequently bedridden(8).

About LY450139

LY450139 inhibits gamma secretase, an enzyme that cuts a protein, creating a shorter, sticky protein called amyloid beta. Alzheimer's disease theory suggests that some subtypes of amyloid beta clump together and eventually kill brain cells. Clinical studies have examined the effect of LY450139 on amyloid beta in blood and cerebrospinal fluid. The most frequently occurring side effects experienced in earlier clinical studies with LY450139 include diarrhea, upset stomach, and fatigue. For a more complete listing of potential side effects, prosp
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
(Date:7/31/2014)... Catylix, Inc. ( Burbank, California ... California ) announced today the formation of ... fluorination products and related chemistry. Developing ... use of substituents that are chemically stable, resistant ... improve binding and bioavailability. Fluorinated functional groups are ...
(Date:7/31/2014)... -- Zacks.com announces the list of stocks featured in the Analyst ... latest news and events impacting stocks and the financial markets. ... BIIB - Free Report ), Gilead (Nasdaq: GILD - ... Report ), AbbVie (NYSE: ABBV - Free Report ) ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... Phase III,clinical trial evaluating the efficacy and safety ... of postmenopausal osteoporosis were,presented at the American Society ... In the non-inferiority study comparing risedronate 150,mg once ... sodium,tablets)] increases in bone mineral density (BMD) were ...
... Sept. 19 Rockwell Medical,Technologies, Inc. (Nasdaq: ... and,developer of concentrates and specialty pharmaceuticals focused ... that it has commenced,enrollment in its Phase ... a physiological iron-maintenance therapy drug. The ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
(Date:8/1/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... J. Jill Suitor, PhD, of Purdue University as ... to Gerontology Award. , This distinguished honor is ... have helped bring about a new synthesis and ... designs addressing a significant problem in the literature. ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Sean P. Curran, PhD, of ... of the Nathan Shock New Investigator Award. , This ... knowledge about aging through basic biological research. It was ... founding member of GSA and pioneer in gerontological research ...
(Date:8/1/2014)... Gerontological Society of America (GSA) the ... aging has chosen Carole B. Lewis, PT, DPT, ... recipient of the Excellence in Rehabilitation of Aging Persons ... acknowledge outstanding contributions in the field of rehabilitation. The ... or patient care, or publications that may include scholarly ...
(Date:8/1/2014)... Lifeinsurancenomedicalexam.info has released a new blog post explaining ... high cholesterol levels. , Clients who have a ... medical exam life insurance. These plans offer a convenient ... Since there are no medical examinations involved, clients who ... a few minutes. However, this convenience comes at a ...
(Date:8/1/2014)... August 01, 2014 Chilton Medical ... that aims to empower patients and their families ... health care by providing easy, secure access to ... patients instant, web-based access to their health information ... results, medications, allergies, demographic information, visit history, discharge/aftercare ...
Breaking Medicine News(10 mins):Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Lewis to receive GSA's 2014 Excellence in Rehabilitation of Aging Persons Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Chilton Medical Center Launches Online Patient Portal 2
... new project is an interdisciplinary research project covering ... has been awarded EUR 6 million from the ... The project will gather scientists from seven countries, ... University of Gothenburg, Sweden. , Those working on ...
... In the rat race of life, one thing is certain: ... in Molecular Ecology finds the same is true ... most form distinct neighborhoods where they spend the majority of ... lively neighborhoods each with its own personality. But scientists ...
... by Erich Lindemann Community Mental Health Education Center Initiative ... of Professional Psychology BOSTON, May 26 "The ... the needs of 1.5 million soldiers and marines and ... Estimates are as high as 33% that these ...
... connect using technology powered by 100 percent ... N.Y., May 26 Optimum Lightpath, a ... New York metropolitan area businesses, today introduced ... available exclusively through Optimum Lightpath to New ...
... Novel Oral Therapies Will Garner 29 Percent of the ... from Decision ResourcesWALTHAM, Mass., May 26 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the approval ... as the increasing use of current and emerging injectable ...
... helps explain association between the two illnesses , , TUESDAY, ... gum disease (periodontitis) and heart disease has been discovered ... coronary heart disease (CHD) has been known for years, ... confirmed. The University of Kiel team found that the ...
Cached Medicine News:Health News:Sahlgrenska Academy to lead major European project on obesity 2Health News:Returning War Veterans: Challenges in Continuing Mental Health Care After Military and Civilian Trauma 2Health News:Returning War Veterans: Challenges in Continuing Mental Health Care After Military and Civilian Trauma 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 2Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 3Health News:Optimum Lightpath(SM) and GetWellNetwork(R) Transform Hospital Bedside Care with Launch of Interactive Patient Care Service 4Health News:Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 2Health News:Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018 3Health News:Gum Disease, Heart Disease Share Genetic Link 2
... designed to validate HDL cholesterol plus other ... This control is compatible with most major ... Synchron and Vitros. HDL values are given ... methods: Dextran Sulfate 50,000 MW. Apolipoprotein A-1 ...
... is intended as a means ... ethanol assay methods. This ready-to-use, ... clinically significant levels of ammonia ... provided for the following instruments: ...
... This unassayed control is intended ... manual and automated assay methods ... oxalate in human urine samples. ... requiring no reconstitution. This control ...
... Microbumin is a two-level control ... Clinitek Microalbumin Reagent Strips and Roche ... also suitable for turbidimetric immunoassays using ... and DCA 2000, Cobas, Diasorin SPQ ...
Medicine Products: